Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/26 10:00:19 pm
56.39 USD   -0.32%
05/26 MERCK : Corporate Social Responsibility Related News Releases and St..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
05/24 MERCK : to Present at the UBS Global Healthcare Conference
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
05/26 MERCK : Corporate Social Responsibility Related News Releases and Story Ideas fo..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
05/24 MERCK : to Present at the UBS Global Healthcare Conference
05/24 MSD ANIMAL HEALTH : Receives Marketing Approval from European Medicines Agency f..
05/24 MERCK : Announces FDA Accepts Samsung Bioepis’ Biologics License Applicati..
05/23 MERCK : Foundation Announces the Alliance to Advance Patient-Centered Cancer Car..
05/23DJGermany's Bayer Offers $62 Billion in Cash for Monsanto
05/19DJGermany's Bayer Breaks With Caution in Monsanto Bid
05/19DJMERCK : New Hope for Melanoma Patients -- Update
05/18 MERCK : New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in A..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials